XBiotech (XBIT) Cash from Investing Activities (2014 - 2025)
XBiotech (XBIT) posted quarterly Cash from Investing Activities of -$34000.0 for Q4 2025, up 59.52% year-over-year from -$21313.4 in Q4 2024, and up 69.09% quarter-over-quarter from -$110000.0 in Q3 2025.
XBiotech (XBIT) Cash from Investing Activities (2014 - 2025) Analysis & Trends
XBiotech's Cash from Investing Activities history runs 12 years deep, the most recent figure standing at -$34000.0 for Q4 2025.
- In Q4 2025, Cash from Investing Activities rose 59.52% year-over-year to -$34000.0; the TTM figure through Dec 2025 stood at -$289000.0 (up 77.84% YoY), while the FY2025 annual figure was -$289000.0, up 77.84% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at -$34000.0, up from -$110000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $61.8 million in Q3 2023, with the low at -$59.7 million in Q3 2022.
- The 5-year median for Cash from Investing Activities is -$184500.0 (2022), against an average of -$375650.0.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 8434.57% in 2022, then jumped 203.49% in 2023.
- XBiotech's Cash from Investing Activities stood at -$476000.0 in 2021, then slumped by 720.8% to -$3.9 million in 2022, then surged by 97.06% to -$115000.0 in 2023, then grew by 26.96% to -$84000.0 in 2024, then surged by 59.52% to -$34000.0 in 2025.
- Business Quant data shows XBIT's Cash from Investing Activities at -$34000.0 in Q4 2025, -$110000.0 in Q3 2025, and -$51000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | XBiotech | 69.51 Mn | 69.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34,000.00 |
| Dec 31, 2025 | -34,000.00 |
| Sep 30, 2025 | -110,000.00 |
| Sep 30, 2025 | -110,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Mar 31, 2025 | -94,000.00 |
| Mar 31, 2025 | -94,000.00 |
| Dec 31, 2024 | -84,000.00 |
| Dec 31, 2024 | -84,000.00 |
| Sep 30, 2024 | -338,000.00 |
| Sep 30, 2024 | -338,000.00 |
| Jun 30, 2024 | -627,000.00 |
| Jun 30, 2024 | -627,000.00 |
| Mar 31, 2024 | -255,000.00 |
| Mar 31, 2024 | -255,000.00 |
| Dec 31, 2023 | -115,000.00 |
| Dec 31, 2023 | -115,000.00 |
| Sep 30, 2023 | 61.83 Mn |
| Sep 30, 2023 | 61.83 Mn |